Mirae Asset Global Investments Co., Ltd. Apellis Pharmaceuticals, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

$28 Billion
Q2 2025

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 4,855 shares of APLS stock, worth $117,248. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,855

Previous 4,200 15.6%

Holding current value

$117,248

Previous $91,000 7.69%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 21, 2025	BUY	$16.36 - $23.0 $10,715 - $15,065	655 Added 15.6%	4,855 $84,000
Q1 2025 Apr 24, 2025	BUY	$21.87 - $34.63 $1,202 - $1,904	55 Added 1.33%	4,200 $91,000
Q4 2024 Jan 27, 2025	SELL	$26.18 - $35.42 $6,780 - $9,173	-259 Reduced 5.88%	4,145 $132,000
Q3 2024 Oct 23, 2024	BUY	$28.84 - $41.15 $22,524 - $32,138	781 Added 21.56%	4,404 $127,000
Q2 2024 Jul 30, 2024	SELL	$38.07 - $59.71 $1.78 Million - $2.79 Million	-46,676 Reduced 92.8%	3,623 $138,000
Q1 2024 May 01, 2024	BUY	$55.39 - $72.47 $2.79 Million - $3.65 Million	50,299 New	50,299 $2.96 Million
Q1 2023 May 04, 2023	BUY	$46.59 - $66.96 $246,134 - $353,749	5,283 Added 11.69%	50,462 $3.33 Million
Q4 2022 Feb 09, 2023	BUY	$43.24 - $61.04 $99,062 - $139,842	2,291 Added 5.34%	45,179 $2.34 Million
Q3 2022 Nov 10, 2022	BUY	$44.76 - $69.66 $633,891 - $986,524	14,162 Added 49.3%	42,888 $2.93 Million
Q2 2022 Jul 26, 2022	BUY	$35.07 - $59.21 $1.01 Million - $1.7 Million	28,726 New	28,726 $1.3 Million

Others Institutions Holding APLS

# of Institutions

297

Shares Held

132M

Call Options Held

2.97M

Put Options Held

623K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.65B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Apellis Pharmaceuticals, Inc. Transaction History